MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) is a biopharmaceutical company focusing on the development of innovative medicines and bringing new therapies for patients with cancer. We conduct clinical trials to obtain safety and efficacy data on investigational product candidates that may meet the requirements for approval by regulatory authorities, providing wider patient accessibility. Clinical trials are controlled research studies in humans designed to determine if an investigational product candidate is safe and effective. MediLink encourages awareness of and participation in our clinical trials. For information regarding MediLink-sponsored clinical trials, please visit  clinicaltrials.gov

Expanded Access, which is sometimes known as “compassionate use”, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational therapy for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.  

Currently, MediLink does not offer an expanded access program. We believe that access to our investigational product candidates should be limited to controlled clinical trials until such time as their safety, tolerability and effectiveness have been determined and confirmed by regulatory authorities.

MediLink recognizes the need for Expanded Access Programs and will re-evaluate the Expanded Access Policy based on data from clinical trials.

If you have questions about MediLink’s expanded access policy, please contact us at info@medilinkthera.com

MediLink may revise this policy at any time.